After exiting stealth mode with $190M today, Marea Therapeutics' Co-Founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more
Cardiology expert Ethan Weiss describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol, Marea's plans beyond this target, and his upcoming Timmerman Traverse hike for charity.